A comparison of efficacy and safety between Chinese generic imatinib and branded imatinib in patients with newly-diagnosed chronic myeloid leukemia in the chronic phase:a single-center prospective cohort study

Objective To compare the efficacy and safety between Chinese generic imatinib(Xinwei~,Jiansu Hansoh Pharmaceutical Group Co.,Ltd.)and branded imatinib(Glivec~,Novartis)in patients with newly-diagnosed chronic myeloid leukemia in chronic phase(CML-CP).Methods Patients with newly diagnosed CML-CP